Drug intelligence / Profile preview

WPC05

Development stage: Preclinical
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules

Overview

WPC05 is a small molecule inhibitor being developed by Westlake Pharmaceuticals for the treatment of cancer. It targets the Mitogen-Activated Protein Kinase (MAPK) pathway, a central signaling cascade that regulates cell growth, proliferation, and survival, and is frequently mutated or overexpressed in various malignancies. By modulating this pathway, WPC05 aims to inhibit tumor progression. As of 2024, the candidate is in the drug discovery phase of development.

Targets

MEK

Beyond the preview

Go deeper on WPC05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPC05.

Explore the full profile